Your browser is no longer supported. Please, upgrade your browser.
PJP PowerShares Dynamic Pharmaceuticals Portfolio daily Stock Chart
PowerShares Dynamic Pharmaceuticals Portfolio
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-0.02%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-6.82%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter2.50%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.12 Perf Half Y-1.09%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-9.01%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range53.55 - 67.74 Perf YTD7.37%
Dividend0.48 P/FCF- EPS past 5Y- ROI- 52W High-11.19% Beta-
Dividend %0.80% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low12.34% ATR0.66
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)35.94 Volatility1.03% 1.01%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.74 Prev Close60.33
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume54.81K Price60.16
Recom- SMA20-3.08% SMA50-3.24% SMA2001.54% Volume40,302 Change-0.28%
Aug-17-17 07:36AM  How Amgens Nephrology Drugs Are Positioned after 2Q17? Market Realist
Aug-10-17 10:36AM  Celgenes Abraxane Continued Steady Growth in 2Q17 Market Realist
Aug-07-17 09:45AM  Q2 Earnings Fail to Impress Pharma ETF Zacks
Aug-04-17 01:57PM  Valeant Pharmaceuticals Intl Inc (VRX) Stock: Stupid Is as Stupid Does InvestorPlace
Aug-01-17 10:41AM  How Gilead Sciences HCV Franchise Is Positioned after 2Q17 Market Realist
09:09AM  Dupixent Could Substantially Drive Regenerons Growth Market Realist
Jul-31-17 04:36PM  Examining Bristol-Myers Squibbs Oncology Portfolios 2Q17 Market Realist
07:40AM  Eli Lilly in 2Q17: Humulin and Endocrine Products Market Realist
Jul-28-17 07:36AM  Behind Pfizers Legacy Established Products Performance in 2017 Market Realist
Jul-14-17 10:37AM  Behind Allergans Business Segments and Revenues Market Realist
Jul-10-17 03:10PM  What Lies Ahead for Pharma ETFs in Second Half 2017 Zacks
10:37AM  How Bristol-Myers Squibb Stock Has Performed in 2Q17 Market Realist
Jul-07-17 12:00PM  Improving Health for This Pharma ETF Investopedia
Jul-05-17 09:06AM  Johnson & Johnsons Consumer Business in 1Q17 Market Realist
Jul-03-17 12:25PM  Gordon Gekko was right: Stocks are now a zero-sum game Yahoo Finance
10:37AM  How Did Keytruda Perform in 1Q17? Market Realist
Jun-30-17 01:44PM  Why the US is losing the war on drug prices: trader Yahoo Finance
11:37AM  Stocks edge up as Q2 draws to a close Yahoo Finance
Jun-29-17 08:00AM  Trending: OPEC Fails to Scare Oil Short-Sellers ETF Database
Jun-27-17 10:36AM  A Look at Pfizers Revenue for 1Q17 Market Realist
Jun-23-17 01:36PM  Why investors flipped 180 on health care stocks today: NYSE trader Yahoo Finance Video
May-30-17 02:02PM  How Johnson & Johnsons Valuation Changed Post-1Q17 Market Realist
May-24-17 10:36AM  Performance of Mercks Diabetes Portfolio in 1Q17 Market Realist
May-11-17 10:36AM  Understanding Allergans Valuation after the 1Q17 Results Market Realist
May-03-17 02:58PM  Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus Zacks
Apr-26-17 09:09AM  Bristol-Myers Squibbs 1Q17 Estimates: Virology Segment Market Realist
Apr-20-17 05:05PM  Johnson & Johnsons 1Q17 Segment-by-Segment Performance Market Realist
Apr-13-17 04:35PM  Johnson & Johnsons 1Q17 Estimates: Pharmaceuticals Segment Market Realist
Apr-11-17 07:36AM  Analyzing the Performance of Abbott Laboratories in 1Q17 Market Realist
Apr-07-17 06:59PM  ETF Flyers: Pharmaceuticals
03:05PM  Performance of Merck & Co. Stock in 1Q17 Market Realist
Apr-04-17 10:36AM  These Key Product Developments Could Help Pfizer Market Realist
10:36AM  These Key Product Developments Could Help Pfizer
Apr-03-17 10:37AM  Recent Developments at Eli Lilly Market Realist
10:37AM  Recent Developments at Eli Lilly
Mar-30-17 09:08AM  How Eli Lillys Business Segments Performed in 2016 Market Realist
09:08AM  How Eli Lillys Business Segments Performed in 2016
Mar-24-17 10:35AM  Bausch & Lomb Continues to be Key Growth Driver for Valeant Market Realist
10:35AM  Bausch & Lomb Continues to be Key Growth Driver for Valeant
Mar-23-17 09:06AM  New Product Launches May Boost Valeants Dermatology Revenue Market Realist
09:06AM  New Product Launches May Boost Valeants Dermatology Revenue
Mar-22-17 10:36AM  Relistor May Be Solid Growth Opportunity for Valeant in 2017 Market Realist
10:36AM  Relistor May Be Solid Growth Opportunity for Valeant in 2017
Mar-20-17 10:22AM  Trump, Biogen and Amgen Hammer Healthcare ETFs Zacks
10:22AM  Trump, Biogen and Amgen Hammer Healthcare ETFs
Mar-15-17 04:33PM  Should You Buy Pharma ETFs Now? Zacks
04:33PM  Should You Buy Pharma ETFs Now?
03:48PM  [$$] Drug Stocks Look Ready To Move Higher
03:48PM  [$$] Drug Stocks Look Ready To Move Higher at
Mar-09-17 04:09AM  Trumps Obamacare Lite presents opportunities and perils for investors at MarketWatch
Mar-08-17 10:07AM  Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs
Mar-03-17 03:35PM  How Mylans Europe Segment Performed
Mar-01-17 08:59AM  Hit ETFs & Stocks from the Top Sector of February
Feb-28-17 09:06AM  Eli Lilly & Co.s Recent Developments
Feb-22-17 10:37AM  Keytruda: Merck & Co.s Immuno-Oncology Blockbuster Drug
Feb-09-17 08:00AM  Trending: Financials Trade Sideways as Trump Prepares Dodd-Frank Rollback
Feb-06-17 09:55AM  Q4 Earnings Faring Well for Pharma ETFs
Feb-01-17 09:06AM  Changes in Bristol-Myers Squibbs 4Q16 Profitability
Jan-25-17 12:05PM  Why Eli Lilly Expects to See Revenue Growth in 4Q16
Jan-19-17 04:06PM  What Lies Ahead for Pharma ETFs?
08:00AM  Trending: Pound Gains as Theresa May Lays out Brexit Plan
Jan-13-17 07:36AM  Mylans Profit Margins: What Made Them Change?
Jan-12-17 07:37AM  Understanding Mylans Revenues
Jan-03-17 07:36AM  Harvoni: Gilead Sciences Blockbuster HCV Drug
Dec-12-16 11:06AM  How Could Pfizer Drive Growth for Ibrance?
Dec-07-16 09:44AM  Pisani: Trump rally is evolving
Dec-02-16 04:05PM  Two Nano-Cap Pharma Stocks To Watch Right Now at Insider Monkey
Dec-01-16 10:05AM  Understanding Mercks Most Recent Product Developments
08:05AM  How Baxter Continues to Contribute to Patient Care
Nov-30-16 08:05AM  Steady Rise: Allergans International Segment in 3Q16
Nov-29-16 11:04AM  How Did Gilead Sciencess HCV Business Perform across Geographies?
10:04AM  How Was Bristol-Myers Squibbs Profitability in 3Q16?
Nov-28-16 11:06AM  Gilead Sciences Holds a Broader HIV Portfolio
Nov-25-16 12:04PM  Bristol-Myers Squibb Continues Revenue Growth in 3Q16
08:04AM  Key Investor Insights into Eli Lillys Recent Developments
Nov-23-16 08:04AM  Beyond Oncology: BMYs Eliquis, a Key Growth Driver
Nov-22-16 03:04PM  Understanding Eli Lillys Business Segments by 3Q16 Performance
10:04AM  Inside Bristols Key to Success: Multiple Labels for Opdivo
Nov-18-16 05:04PM  Understanding Bristols Blockbuster: Opdivos Edge over Keytruda
Nov-11-16 05:05PM  November Surprise Rallies Stocks
Nov-10-16 11:26AM  The death of Obamacare will bring new opportunities for investors at MarketWatch
Nov-07-16 11:42AM  Mr. Wonderful's Election Week Trades For A Trump Victory
Nov-01-16 10:04AM  What Will Be Pfizers Profitability in 3Q16?
Oct-20-16 05:48PM  Another Health Care Chart Looks Sick
Oct-19-16 08:06AM  Eli Lillys 3Q16 Estimates: Expect Revenue Growth!
Oct-11-16 11:04AM  BMY Waiting to Enter the First-Line Lung Cancer Space
Oct-07-16 01:16PM  Is the Dividend ETF Bull Run Over?
Oct-05-16 09:42AM  3 ETFs to Buy for a Media Merger Frenzy
Oct-03-16 10:05AM  Why Generic Drugs Will Play a Key Role in the Future
08:05AM  Medicare Negotiations Would Lead to Huge Cost Savings
Sep-30-16 07:04PM  Understanding Mercks Business Segments and Their Revenue Trends
03:04PM  Analyzing Donald Trumps Free-Market Healthcare
01:04PM  How Does Hillary Clinton Plan to Tame Drug Prices?
11:15AM  Generic Drugs Are Crucial in Cost Savings and Accessibility
Sep-26-16 10:05AM  And Then Theres Mylans Specialty Segment, Home of the EpiPen
08:06AM  Whats Driving Growth in Mylans Generics Segment?
Sep-23-16 07:04PM  Generics or Specialty: Which Mylan Segment Is Growing Fastest?
Sep-22-16 10:00AM  Trending on Politics and Central Banks Move Markets
Sep-19-16 06:50PM  A Breakdown Here In This Sector Would Not Be Healthy
Sep-01-16 11:04AM  How Are Eli Lillys Business Segments Performing?
The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Pharmaceutical IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of pharmaceutical companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 23 U.S. pharmaceuticals companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.